CN117797081A - Oil-control, soothing and acne-removing composition as well as preparation method and application thereof - Google Patents
Oil-control, soothing and acne-removing composition as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN117797081A CN117797081A CN202410003167.7A CN202410003167A CN117797081A CN 117797081 A CN117797081 A CN 117797081A CN 202410003167 A CN202410003167 A CN 202410003167A CN 117797081 A CN117797081 A CN 117797081A
- Authority
- CN
- China
- Prior art keywords
- composition
- parts
- acne
- extract
- soothing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 151
- 206010000496 acne Diseases 0.000 title claims abstract description 75
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 102
- 244000299461 Theobroma cacao Species 0.000 claims abstract description 23
- 235000009470 Theobroma cacao Nutrition 0.000 claims abstract description 22
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 claims abstract description 15
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 claims abstract description 15
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940090813 madecassoside Drugs 0.000 claims abstract description 15
- 241001071795 Gentiana Species 0.000 claims abstract description 11
- 235000014826 Mangifera indica Nutrition 0.000 claims description 21
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 claims description 17
- 229960001915 hexamidine Drugs 0.000 claims description 17
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 17
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 17
- 235000004936 Bromus mango Nutrition 0.000 claims description 16
- 235000009184 Spondias indica Nutrition 0.000 claims description 16
- 238000000855 fermentation Methods 0.000 claims description 16
- 230000004151 fermentation Effects 0.000 claims description 16
- 244000086363 Pterocarpus indicus Species 0.000 claims description 15
- 235000009984 Pterocarpus indicus Nutrition 0.000 claims description 15
- 241000186660 Lactobacillus Species 0.000 claims description 14
- 229940039696 lactobacillus Drugs 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 240000007263 Pinus koraiensis Species 0.000 claims description 12
- 235000011615 Pinus koraiensis Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 240000007228 Mangifera indica Species 0.000 claims description 8
- 230000001815 facial effect Effects 0.000 claims description 7
- 235000018782 Dacrydium cupressinum Nutrition 0.000 claims description 6
- 235000013697 Pinus resinosa Nutrition 0.000 claims description 6
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000686 essence Substances 0.000 claims description 2
- 240000006055 Dacrydium cupressinum Species 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 38
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 12
- 230000002195 synergetic effect Effects 0.000 abstract description 7
- 241001135871 Gentiana scabra Species 0.000 abstract description 6
- 208000003251 Pruritus Diseases 0.000 abstract description 6
- 210000003205 muscle Anatomy 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 43
- 210000003491 skin Anatomy 0.000 description 35
- 239000000047 product Substances 0.000 description 31
- 239000007858 starting material Substances 0.000 description 24
- 230000004054 inflammatory process Effects 0.000 description 19
- 206010061218 Inflammation Diseases 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 15
- 241001093152 Mangifera Species 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 10
- 210000002374 sebum Anatomy 0.000 description 10
- 239000002537 cosmetic Substances 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
- 230000001276 controlling effect Effects 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 239000002158 endotoxin Substances 0.000 description 7
- 240000005020 Acaciella glauca Species 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 210000001732 sebaceous gland Anatomy 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 244000017106 Bixa orellana Species 0.000 description 5
- 235000006010 Bixa orellana Nutrition 0.000 description 5
- 241000123326 Fomes Species 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 235000012978 bixa orellana Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 241000186427 Cutibacterium acnes Species 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003098 androgen Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 229940055019 propionibacterium acne Drugs 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- 229960003604 testosterone Drugs 0.000 description 4
- YCVPRTHEGLPYPB-VOTSOKGWSA-N trans-pinosylvin Chemical compound OC1=CC(O)=CC(\C=C\C=2C=CC=CC=2)=C1 YCVPRTHEGLPYPB-VOTSOKGWSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 206010015946 Eye irritation Diseases 0.000 description 3
- 241000283977 Oryctolagus Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 230000003255 anti-acne Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 231100000013 eye irritation Toxicity 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- YCVPRTHEGLPYPB-UHFFFAOYSA-N pinosylvine Natural products OC1=CC(O)=CC(C=CC=2C=CC=CC=2)=C1 YCVPRTHEGLPYPB-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 description 1
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 244000306301 Caesalpinia sappan Species 0.000 description 1
- 235000015162 Caesalpinia sappan Nutrition 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 206010051559 Corneal defect Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 240000008632 Cota tinctoria Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000308505 Filipendula ulmaria Species 0.000 description 1
- 235000016622 Filipendula ulmaria Nutrition 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- DUAGQYUORDTXOR-GPQRQXLASA-N Gentiopicrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](C=C)C2=CCOC(=O)C2=CO1 DUAGQYUORDTXOR-GPQRQXLASA-N 0.000 description 1
- DUAGQYUORDTXOR-WULZUDSJSA-N Gentiopicrin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@@H](C=C)C=2C(C(=O)OCC=2)=CO1 DUAGQYUORDTXOR-WULZUDSJSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 235000005205 Pinus Nutrition 0.000 description 1
- 241000218602 Pinus <genus> Species 0.000 description 1
- 235000000405 Pinus densiflora Nutrition 0.000 description 1
- 240000008670 Pinus densiflora Species 0.000 description 1
- 235000008582 Pinus sylvestris Nutrition 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 239000010404 Scutellaria baicalensis extract Substances 0.000 description 1
- 208000015390 Sebaceous gland disease Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000001727 Tropicoporus linteus Species 0.000 description 1
- 240000004482 Withania somnifera Species 0.000 description 1
- 235000001978 Withania somnifera Nutrition 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000001140 aloe barbadensis leaf extract Substances 0.000 description 1
- 229940069638 aloe vera leaf extract Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940059958 centella asiatica extract Drugs 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 1
- RGUVUPQQFXCJFC-UHFFFAOYSA-N n-hydroxyoctanamide Chemical compound CCCCCCCC(=O)NO RGUVUPQQFXCJFC-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001839 pinus sylvestris Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033785 sebaceous gland development Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- MJMNMZORBRTNGP-NFOLICFBSA-J tetrasodium;[(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-[[[[(2r,3s,4r,5r)-5-(3-carbamoyl-4h-pyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl]oxymethyl]-4-hydroxyoxolan-3-yl] phosphate;tetrahydrate Chemical compound O.O.O.O.[Na+].[Na+].[Na+].[Na+].C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](OP([O-])([O-])=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 MJMNMZORBRTNGP-NFOLICFBSA-J 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cosmetics (AREA)
Abstract
The invention provides an oil-control, relieving and acne-removing composition, and a preparation method and application thereof, wherein the oil-control, relieving and acne-removing composition comprises the following components: composition I, composition II and composition III; the composition I comprises gentian extract, cocoa seed extract and madecassoside. The invention combines the GENTIANA SCABRA root extract, the cocoa (THEOBROMA CACAO) seed extract and the madecassoside, and the synergistic effect can jointly promote the composition to exert the anti-inflammatory and soothing effects; the composition I, the composition II and the composition III are matched and combined in a specific proportion, and the obtained oil control, relief and acne removal composition has good oil control, relief and acne removal effects, can effectively improve the itch and redness problems of skin, and is suitable for sensitive muscles.
Description
Technical Field
The invention belongs to the technical field of cosmetics, and particularly relates to an oil-control, soothing and acne-removing composition, and a preparation method and application thereof.
Background
Acne generally refers to acne, belongs to one of the most common chronic inflammatory skin diseases, is an inflammatory reaction caused by the fact that skin cannot normally excrete grease, and has high pathogenicity, and mainly occurs on the face and the back.
Sensitive skin refers in particular to the highly reactive state of the skin, which occurs under physiological or pathological conditions, mainly affecting the face. Subjective symptoms such as burning, stinging, itching, tightness and the like easily appear on the skin under the stimulation of chemical and mental factors, and objective signs such as erythema, scales, telangiectasia and the like are or are not generated.
Acne is a chronic inflammation of hair follicles and sebaceous glands, and mainly occurs in the face and chest and back in the fatty areas. The occurrence of acne is closely related to the factors such as excessive sebum secretion, keratosis and blockage of the pilosebaceous canal, propionibacterium acnes infection, inflammatory reaction and the like. The pathogenesis of acne is that physical development leads to vigorous androgen secretion in the body, while androgens dominate sebaceous glands to produce more sebum, which is mixed with the shed epidermal tissue to block pores and cause acne.
Particularly, after the puberty is entered, the level of androgens, particularly testosterone, in the human body is rapidly increased, sebaceous gland development is promoted, a large amount of sebum is produced, meanwhile, the abnormal keratinization of the pilosebaceous duct causes the blockage of the duct, sebum discharge is blocked, and a cutin suppository, namely micro acne, is formed. Bacterial infections secondary to the disorders of secretion and excretion of large amounts of sebum, the presence of a variety of microorganisms such as propionibacterium acnes, staphylococcus albus and malassezia furfur in hair follicles, which have been previously known as sebaceous gland disorders, are essentially damaging to include hair follicles, sebaceous glands and epidermis.
CN114469829a discloses a composition for improving skin acne and inflammation and application thereof, and aims to provide a composition for relieving skin acne and inflammation, inhibiting sebum secretion, inhibiting inflammatory reaction, preventing inflammatory factor from generating, timely moisturizing and repairing skin barrier; the composition comprises the following components in parts by weight: 6-10 parts of aloe vera leaf extract, 6-10 parts of medicinal layer porus extract, 4-8 parts of centella asiatica extract, 4-8 parts of kuh-seng extract, 4-8 parts of scutellaria baicalensis extract, 1-2 parts of fermentation product filtrate of two-split yeast, 1-2 parts of saccharomycete polypeptide, 1-2 parts of menthol lactate, 730.01-0.05 part of quaternary ammonium salt, 0.05-0.1 part of octanoyl hydroxamic acid, 1-2 parts of ethylhexyl glycerol, 10-20 parts of butanediol and 15-25 parts of deionized water.
CN110025538A discloses a composition for improving skin acne and inflammation and application thereof, which aims to provide a composition which has synergistic ingredients, can well control sebum secretion, resist bacteria and diminish inflammation, can inhibit active oxygen free radicals to achieve oxidation resistance, and can effectively improve skin acne and inflammation when applied to cosmetics, and comprises the following components in parts by weight: 1-7 parts of pinus koraiensis leaf extract, 1-5 parts of golden chamomile extract, 2-6 parts of sappan wood extract, 0.5-3 parts of European corydalis tuber extract and 1-4 parts of withania root extract; belongs to the technical field of cosmetics.
CN114177107a discloses an acne-removing composition, a preparation method and application thereof. The acne-removing composition is used for exfoliating cutin by mild papain, dredging sebaceous glands of hair, enabling an active ingredient quaternary ammonium salt-73 with antibacterial and antimicrobial effects to better play a role, and palmitoyl tetrapeptide-7 is used for reducing inflammatory factors and eliminating skin inflammation, so that the spiraea ulmaria extract is used for balancing an epidermal ecosystem to form natural antibacterial protection, regulating sebaceous gland secretion, astringing pores and improving skin texture conditions; the acne-removing composition has a good inhibition effect on propionibacterium acnes, and each component in the acne-removing composition has a synergistic effect on inhibiting the increase of the content of facial skin grease, and has no stimulation.
Therefore, development of a composition which can reduce the irritation of the product to skin and simultaneously effectively control oil, relieve and remove acne is the focus of research in the field.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide an oil-control, relieving and acne-removing composition, a preparation method and application thereof, which can effectively improve the problems of acne, pruritus, redness and the like of skin.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
in a first aspect, the invention provides an oil control, soothing and acne-removing composition, which is characterized by comprising the following components in percentage by weight: composition I, composition II and composition III.
The composition I comprises radix Gentianae (GENTIANA SCABRA) root extract, cocoa (Theobroma CACAO) seed extract and madecassoside.
Preferably, the composition II comprises a pharmaceutical layer porus (FOMES OFFICINALIS) extract and a rosewood (BIXA ORELLANA) seed extract.
Preferably, the composition III comprises Pinus koraiensis (Pinus koraiensis) leaf extract, lactobacillus fermentum fermentation product, mango (MANGIFERA INDICA) leaf extract, quaternary ammonium salt-73 and hexamidine bis (isethionate).
The radix Gentianae (GENTIANA SCABRA) root extract mainly comprises gentiopicroside, gentiobiose and gentisic acid, has effects of inhibiting irritation and inflammation, promoting secretion of epidermal cell cholesterol, and improving oily rough skin state. The cocoa seed extract can inhibit histamine release when the skin is sensitive, and has certain antiallergic and soothing effects. The extract of cocoa (Theobroma CACAO) seed has inhibiting effect on inflammatory factors such as metalloprotease, and can restore acid-base balance of skin sebum membrane, and can help skin preserve moisture. The madecassoside has antioxidant, antibacterial, immunity regulating, antiinflammatory, tranquilizing, skin regeneration promoting, and skin texture improving effects. The invention combines the GENTIANA SCABRA root extract, the cocoa (THEOBROMA CACAO) seed extract and the madecassoside, and the synergistic effect can jointly promote the composition to exert the anti-inflammatory and soothing effects.
The core efficacy substances of the medicinal lamellar porus (FOMES OFFICINALIS) extract are various active ingredients such as triterpene, sesquiterpene, polyphenol, polysaccharide and the like, have the functions of resisting oxidation and relieving and repairing, realize the effects of controlling oil and astringing pores, and are more suitable for sensitive muscles. The extract of rosewood (BIXA ORELLANA) seed can inhibit the action of androgen and growth promoting factor IGF-1 on lipid cells, reduce sebaceous gland activity, reduce sebum secretion, shrink pores, and reduce acne bacillus virulence. The research of the invention discovers that the medicinal layer porus (FOMES OFFICINALIS) extract and the rosewood seed extract are combined for use, so that the effects of controlling oil and shrinking pores can be jointly exerted under the synergistic effect.
The pinosylvin (Pinus sylvestris) leaf extract is rich in pinosylvin, has strong antioxidant and antiinflammatory effects, and can effectively resist free radical damage and skin inflammatory reaction, and protect skin health. The lactobacillus fermentation product contains a plurality of beneficial bacteria, can inhibit the growth of bacteria and fungi on the surface of skin, reduce the occurrence of skin infection and inflammation, alleviate the problems of skin sensitivity, red swelling and the like, recover the self-resisting capacity of sensitive skin, strengthen the skin barrier, have the function of astringing, can effectively shrink pores, improve the greasy condition of skin and make the skin more fresh. Mango (MANGIFERA INDICA) leaf extract is effective in reducing Propionibacterium acnes activity, reducing porphyrin strength and effects on inflammation, restoring skin to non-acne prone skin, protecting skin flora, and making skin healthier. Can also inhibit and reduce sebum production. The quaternary ammonium salt-73 is used as a high-efficiency broad-spectrum antibacterial agent, can quickly break down cell walls and cell membranes of gram-positive bacteria such as acne short-rod bacterin and the like, and can degrade the cells, thereby playing the acne-removing effect. Hexamidine bis (isethionate) is a water-soluble cationic substance with broad-spectrum resistance against various gram-positive and negative bacteria and various mold and yeast. The invention combines the PINUS DENSIFLORA (PINUS denseflora) leaf extract, mango (MANGIFERA INDICA) leaf extract, rosewood (BIXA ORELLANA) seed extract, quaternary ammonium salt-73 and hexamidine bis (hydroxyethylsulfonate) salt for use, thereby jointly playing the effects of anti-inflammatory and acne removal.
Preferably, the mass ratio of composition I, composition II and composition III is (12.7-37): (34-46): (5.6-16.5), which may be, for example, 12.7:34:5.6, 12.7:40:5.6, 12.7:46:5.6, 20:34:8, 20:40:8, 20:46:8, 30:34:12, 30:40:12, 30:46:12, 37:34:16.5, 37:40:16.5, 37:46:16.5.
Preferably, the composition I comprises 2.5-15 parts (for example, 3 parts, 5 parts, 8 parts, 10 parts, 12 parts, 14 parts, etc.), 0.2-2 parts (for example, 0.3 parts, 1 part, 1.5 parts, etc.), 10-20 parts (for example, 11 parts, 12 parts, 14 parts, 16 parts, 18 parts, 19 parts, etc.) of the gentian extract in parts by weight.
Preferably, the composition II comprises 30-40 parts (for example, 31 parts, 33 parts, 35 parts, 38 parts, 39 parts, etc.) of the medicinal layer fungus extract and 4-6 parts (for example, 4.5 parts, 5 parts, 5.5 parts, etc.) of the rosewood seed extract in parts by weight.
Preferably, the composition III comprises 1-3 parts (for example, 1.5 parts, 2 parts, etc.), 0.5-3 parts (for example, 1 part, 1.5 parts, 2 parts, 2.5 parts, etc.), 2-4.5 parts (for example, 2.5 parts, 3 parts, 3.5 parts, 4 parts, etc.), 0.1-0.5 part (for example, 0.2 part, 0.3 part, 0.4 part, 0.45 part, etc.), 1-5 parts (for example, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 4 parts, 4.5 parts, etc.) of hexamidine bis (hydroxyethylsulfonate.
Preferably, the oil-control, soothing and acne-removing composition further comprises 0.5-10 parts (for example, 1 part, 3 parts, 5 parts, 10 parts and the like) of butanediol and 0.5-48 parts (for example, 10 parts, 20 parts, 30 parts, 40 parts, 45 parts, 48 parts and the like) of water.
In a second aspect, the present invention provides a method for preparing the oil-control, soothing and acne-removing composition according to the first aspect, the method comprising: and uniformly mixing the composition I, the composition II and the composition III to obtain the composition.
In a third aspect, the invention provides an application of the oil-control, soothing and acne-removing composition according to the first aspect in water emulsion, essence, face cream or face cleaning products.
Preferably, the oil-control, soothing and acne-removing composition according to the first aspect of the present invention is 1-2% by mass, for example, 1%, 1.2%, 1.4%, 1.6%, 1.8%, 2% by mass, etc. of the aqueous emulsion, essence, cream or cleansing product.
The numerical ranges recited herein include not only the recited point values, but also any point values between the recited numerical ranges that are not recited, and are limited to, and for the sake of brevity, the invention is not intended to be exhaustive of the specific point values that the recited range includes.
Compared with the prior art, the invention has the following beneficial effects:
1. the invention combines the GENTIANA SCABRA root extract, the cocoa (THEOBROMA CACAO) seed extract and the madecassoside, and the synergistic effect can jointly promote the composition to exert the anti-inflammatory and soothing effects.
2. The invention combines the medicinal layer porus (FOMES OFFICINALIS) extract and the rosewood (BIXA ORELLANA) seed extract, and can play roles of controlling oil and shrinking pores together under synergistic action.
3. The invention combines the pinus koraiensis (pinus koraiensis) leaf extract, lactobacillus fermentation product, mango (MANGIFERAINDICA) leaf extract, quaternary ammonium salt-73 and hexamidine bis (isethionic acid) salt for use, thereby jointly playing the effects of anti-inflammatory and acne removal.
4. The 10 components are matched and combined in a specific proportion, and the obtained composition has good effects of controlling oil, relieving inflammation and removing acne, can effectively improve the itching and redness of skin, and is suitable for sensitive muscles.
Drawings
FIG. 1 is a chart showing the condition of skin inflammation pimples before using the product of application example 1;
FIG. 2 is a chart showing the inflammatory papules of the skin after 2 weeks using the product of application example 1.
Detailed Description
The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the examples are merely to aid in understanding the invention and are not to be construed as a specific limitation thereof.
The terms "comprising," "including," "having," "containing," or any other variation thereof, are intended to cover a non-exclusive inclusion. For example, a composition, step, method, article, or apparatus that comprises a list of elements is not necessarily limited to only those elements but may include other elements not expressly listed or inherent to such composition, step, method, article, or apparatus.
"optional" or "any" means that the subsequently described event or event may or may not occur, and that the description includes both cases where the event occurs and cases where the event does not.
The indefinite articles "a" and "an" preceding an element or component of the invention are not limited to the requirement (i.e. the number of occurrences) of the element or component. Thus, the use of "a" or "an" should be interpreted as including one or at least one, and the singular reference of an element or component includes the plural reference unless the amount clearly dictates otherwise.
The description of the terms "one embodiment," "some embodiments," "exemplarily," "specific examples," or "some examples," etc., herein described means that a specific feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the present invention. In this document, the schematic representations of the above terms are not necessarily for the same embodiment or example.
In the present invention, percentages and percentages are by mass unless explicitly stated otherwise. Unless otherwise specified, all experimental procedures used are conventional and all materials, reagents, etc. used are commercially available.
GENTIANA SCABRA root extract: guangzhou Yun Li Biotech Co., ltd;
cocoa (theobrema CACAO) seed extract: blumlight TM biofunctional；
Madecassoside: chenprofen Biotechnology Co., ltd;
extract of phellinus linteus (FOMES OFFICINALIS): laricyl TM BC10111；
Lactobacillus fermentation product: french Sibirch QUORASTOP/skin care;
pinus koraiensis (pinus koraiensis) leaf extract: french Sibirch QUORASTOP/skin care;
mango (MANGIFERA INDICA) leaf extract: manginxyl TM ；
Rosewood (BIXA ORELLANA) seed extract: bix' Activ TM BC10050；
Quaternary ammonium salt-73: CAS number 15763-48-1;
hexamidine bis (isethionic acid) salt: CAS number 659-40-5.
Example 1
The embodiment provides an oil-control, relieving and acne-removing composition, which comprises 36 parts of composition I, 40 parts of composition II, 15.25 parts of composition III, 6 parts of butanediol and the balance of deionized water (the total amount is 100 parts);
the composition I comprises: 15 parts of gentian extract, 1 part of cocoa seed extract and 20 parts of madecassoside;
composition II comprises: 34 parts of medicinal layer porus extract and 6 parts of rosewood seed extract;
composition III comprises: 3 parts of pinus koraiensis leaf extract, 3 parts of lactobacillus fermentation product, 4 parts of mango leaf extract, 0.25 part of quaternary ammonium salt-73 and 5 parts of hexamidine bis (hydroxyethyl sulfonate);
the preparation method comprises the following steps: and uniformly mixing the raw materials according to the formula amount to obtain the traditional Chinese medicine.
Example 2
The embodiment provides an oil-control, relieving and acne-removing composition, which comprises 21 parts of composition I, 40 parts of composition II, 10.1 parts of composition III, 10 parts of butanediol and the balance of deionized water (the total amount is 100 parts);
the composition I comprises: 10 parts of gentian extract, 1 part of cocoa seed extract and 10 parts of madecassoside;
composition II comprises: 35 parts of medicinal layer porus extract and 5 parts of rosewood seed extract;
composition III comprises: 2 parts of pinus koraiensis leaf extract, 2 parts of lactobacillus fermentation product, 3 parts of mango leaf extract, 0.1 part of quaternary ammonium salt-73 and 3 parts of hexamidine bis (hydroxyethyl sulfonate);
the preparation method comprises the following steps: and uniformly mixing the raw materials according to the formula amount to obtain the traditional Chinese medicine.
Example 3
The embodiment provides an oil-control, relieving and acne-removing composition, which comprises 12.7 parts of composition I, 34 parts of composition II, 4.6 parts of composition III, 10 parts of butanediol and the balance of deionized water (the total amount is 100 parts);
the composition I comprises: 2.5 parts of gentian extract, 0.2 parts of cocoa seed extract and 10 parts of madecassoside;
composition II comprises: 30 parts of medicinal layer porus extract and 4 parts of rosewood seed extract;
composition III comprises: 1 part of pinus koraiensis leaf extract, 0.5 part of lactobacillus fermentation product, 2 parts of mango leaf extract, 0.1 part of quaternary ammonium salt-73 and 1 part of hexamidine bis (isethionate);
the preparation method comprises the following steps: and uniformly mixing the raw materials according to the formula amount to obtain the traditional Chinese medicine.
Example 4
The embodiment provides an oil control, relieving and acne removing composition, which is different from the embodiment 1 only in that gentian extract is not added into the composition I, the total amount of the composition I is kept unchanged, and the insufficient part is complemented by cocoa seed extract and madecassoside according to the mass ratio of 1:20; other starting materials, starting materials and preparation methods refer to example 1.
Example 5
The embodiment provides an oil control, relieving and acne removing composition, which is different from the embodiment 1 only in that the cocoa seed extract is not added in the composition I, the total amount of the composition I is kept unchanged, and the insufficient part is complemented by gentian extract and madecassoside according to the mass ratio of 15:20; other starting materials, starting materials and preparation methods refer to example 1.
Example 6
The embodiment provides an oil control, relieving and acne removing composition, which is different from the embodiment 1 only in that no madecassoside is added into the composition I, the total amount of the composition I is kept unchanged, and the insufficient part is complemented by gentian extract and cocoa seed extract according to a mass ratio of 15:1; other starting materials, starting materials and preparation methods refer to example 1.
Example 7
The present example provides an oil-controlling, soothing, acne-removing composition which differs from example 1 only in that the medicinal layer porus extract is not added to composition II, and the rosewood seed extract is adjusted to 40 parts; other starting materials, starting materials and preparation methods refer to example 1.
Example 8
The present example provides an oil-controlling, soothing, acne-removing composition which differs from example 1 only in that the rosewood seed extract is not added to composition II, and the medicinal layer porus extract is adjusted to 40 parts; other starting materials, starting materials and preparation methods refer to example 1.
Example 9
The embodiment provides an oil control, relieving and acne removing composition, which is different from the embodiment 1 only in that the pinus koraiensis leaf extract is not added in the composition III, the total amount of the composition III is kept unchanged, and the insufficient parts are complemented by lactobacillus fermentation products, mango leaf extract, quaternary ammonium salt-73 and hexamidine bis (hydroxyethyl sulfonate) salt according to the mass ratio of 3:4:0.25:5; other starting materials, starting materials and preparation methods refer to example 1.
Example 10
The embodiment provides an oil control, relieving and acne removing composition, which is different from the embodiment 1 only in that lactobacillus fermentation products are not added in the composition II, the total amount of the composition III is kept unchanged, and the insufficient parts are complemented by red pine leaf extract, mango leaf extract, quaternary ammonium salt-73 and hexamidine bis (hydroxyethyl sulfonate) salt according to a mass ratio of 3:4:0.25:5; other starting materials, starting materials and preparation methods refer to example 1.
Example 11
The embodiment provides an oil control, relieving and acne removing composition, which is different from the embodiment 1 only in that mango leaf extract is not added in the composition III, the total amount of the composition III is kept unchanged, and the insufficient part is complemented by red pine leaf extract, lactobacillus fermentation product, quaternary ammonium salt-73 and hexamidine bis (hydroxyethyl sulfonate) salt according to the mass ratio of 3:3:0.25:5; other starting materials, starting materials and preparation methods refer to example 1.
Example 12
The embodiment provides an oil control, relieving and acne removing composition, which is different from the embodiment 1 only in that quaternary ammonium salt-73 is not added into the composition III, the total amount of the composition III is kept unchanged, and the insufficient parts are complemented by red pine leaf extract, lactobacillus fermentation product, mango leaf extract and hexamidine bis (hydroxyethyl sulfonate) salt according to a mass ratio of 3:3:4:5; other starting materials, starting materials and preparation methods refer to example 1.
Example 13
The embodiment provides an oil control, relieving and acne removing composition, which is different from the embodiment 1 only in that hexamidine di (hydroxyethyl sulfonate) is not added into the composition III, the total amount of the composition III is kept unchanged, and the deficient part is complemented by red pine leaf extract, lactobacillus fermentation product, mango leaf extract and quaternary ammonium salt-73 according to the mass ratio of 3:3:4:0.25; other starting materials, starting materials and preparation methods refer to example 1.
Example 14
This example provides an oil control, soothing, acne treatment composition which differs from example 1 only in that composition I is adjusted to 33.25 parts, composition III is adjusted to 18 parts; other starting materials, starting materials and preparation methods refer to example 1.
Example 15
This example provides an oil control, soothing, acne treatment composition which differs from example 1 only in that composition I is 40 parts and composition II is 36 parts; other starting materials, starting materials and preparation methods refer to example 1.
Test example 1
Anti-inflammatory experiment
RAW264.7 macrophages were used as subjects to establish a model of cellular inflammation by stimulating cells with lipopolysaccharide LPS (bacterial endotoxin). Macrophages were inoculated into 12-well plates, incubated in an incubator at 37℃with 5% CO2 aeration for 24 hours, the compositions of the examples were added separately, LPS (1. Mu.g/mL) was added after 2 hours, and the group to which no diluent was added and the group to which no LPS was added were added, stimulated for 24 hours, and the supernatant was collected, centrifuged, and detected. The level of proinflammatory inflammatory factor TNF-alpha release from RAW264.7 was analyzed using ELISA kit.
TNF-alpha inhibition ratio (%) = [ (LPS stimulated inflammatory factor concentration-test agent active inflammatory factor concentration)/(LPS stimulated inflammatory factor concentration-non-stimulated inflammatory factor concentration) ]. Times.100%.
The higher the TNF- α inhibition, the better the anti-inflammatory effect. The TNF- α inhibition test results are shown in Table 1.
Test example 2
Oil control test
Preparation of the reagent:
testosterone (T) solution: precisely weighing 28.8mg testosterone, and fixing volume with absolute ethyl alcohol until the concentration is 4mmol/L; NADPH solution: precisely weighing 42.5mg of NADPH tetrasodium salt, and fixing the volume to 25mL with water, wherein the concentration is 2mmol/L; enzyme extraction buffer solution: 0.32mol/L sucrose, 0.1mmol/L DTT,20mmol/L sodium phosphate, pH6.5. The reaction solution: 1mmol/L DTT,20mmo/L sodium phosphate.
Assay of 5α -reductase inhibitor activity:
the reaction components were sequentially (155. Mu.L of reaction solution, constant temperature at 37 ℃ C.; 12. Mu.L of testosterone; 10. Mu.L of NADPH; 20. Mu.L of the composition of the sample example; 20. Mu.L of 5. Alpha. -reductase) and the change in absorbance of the reaction system at 340nm within 4 minutes was continuously monitored. According to the calculation formulas of the NADPH standard curve, the inhibitor activity unit and the inhibition percentage, the inhibition rate of the 5 alpha-reductase can be calculated.
Inhibitor activity unit definition: in a reaction system at 37 ℃, one enzyme activity unit is deactivated to one inhibitor activity unit. Percent inhibition = (inhibitor activity/enzyme activity) ×100%. The test results are shown in Table 1.
TABLE 1
| Composition sample | TNF-alpha inhibition (%) | 5 alpha-reductase inhibition ratio (%) |
| Example 1 | 56.3 | 79.8 |
| Example 2 | 55.8 | 78.3 |
| Example 3 | 54.7 | 77.9 |
| Example 4 | 43.1 | 66.8 |
| Example 5 | 44.3 | 63.6 |
| Example 6 | 40.7 | 60.3 |
| Example 7 | 47.2 | 40.5 |
| Example 8 | 48.7 | 45.2 |
| Example 9 | 35.2 | 61.5 |
| Example 10 | 38.5 | 65.3 |
| Example 11 | 45.6 | 66.9 |
| Example 12 | 30.7 | 57.2 |
| Example 13 | 32.8 | 55.7 |
| Example 14 | 57.1 | 70.3 |
| Example 15 | 56.8 | 67.2 |
According to the table data, when three components of gentian extract, cocoa seed extract and madecassoside in the composition I are matched for use, the effect is optimal, and the lack of any one component can have a larger influence on the anti-inflammatory effect of the composition, and meanwhile, the oil control effect is slightly influenced; when the composition II in the oil control, relief and acne removal composition comprises a medicinal layer porus extract and a lactobacillus fermentation product, the effect is optimal, and the lack of any one component has an influence on the anti-inflammatory effect, and mainly influences the effects of controlling oil and shrinking pores of the composition; when the red pine leaf extract, the mango leaf extract, the rosewood seed extract, the quaternary ammonium salt-73 and the hexamidine di (isethionic acid) salt in the composition III are used in a matched mode, the anti-inflammatory and acne-removing effects of the components are fully exerted, any one component is absent, the acne-removing effects are affected, and the oil control effects are slightly affected. As is clear from examples 1 to 3 and examples 14 to 15, when the mass ratio of the composition I to the composition II to the composition III is (12.7 to 37): (34 to 46): (5.6 to 16.5), the effects of relieving inflammation and controlling oil to shrink pores are best, and when the ratio of the composition III is too high, the effects of relieving inflammation and controlling oil are less, but adverse reactions such as skin itching and stinging can be caused, and when the ratio of the composition I is too high, the effects of relieving inflammation are little, and the effects of relieving and controlling oil are mainly affected.
Application example 1
The application example provides an amino acid type facial cleanser, and the components of the facial cleanser are shown in table 2:
TABLE 2
The preparation method comprises the following steps:
1. adding water, chelating agent, humectant, thickener, cleaning agent and foam stabilizer into a reaction kettle, setting the temperature to 80-85deg.C, heating and stirring until the material is completely dissolved.
2. Stirring and cooling to 45-55deg.C, adding skin conditioner, antiseptic, aromatic and pH regulator, stirring, filtering, and discharging.
Application examples 2 to 3
The application example provides an amino acid type facial cleanser, which is different from the embodiment 1 only in that the oil control, relief and acne removal composition prepared in the embodiment 1 is replaced by the oil control, relief and acne removal composition in the embodiment 2-3 with the same amount; reference is made to application example 1 for other raw materials, amounts and preparation methods.
Comparative application example 1
The comparative application example provides an amino acid type facial cleanser which is different from example 1 only in that the oil control, soothing and acne removing composition prepared in example 1 is not added; reference is made to application example 1 for other raw materials, amounts and preparation methods.
Test example 3
Product safety evaluation
Acute eye irritation test
The experimental animals were New Zealand rabbits, male, 3 in number. The tested animal is adapted to the animal house in the common environment for 3 days (d), animal quarantine is completed, and the test is carried out after animal health is confirmed. The test object is stock solution of application example 1.
The testing method comprises the following steps:
(1) the eyes of Japanese white rabbits were examined 24 hours before the test, and the animals selected were free from eye irritation symptoms, corneal defects and conjunctival lesions.
(2) The method for contamination comprises the following steps: in the test, 0.1mL of the test substance was instilled into the conjunctival sac of the left eye of a white rabbit with Japanese big ear, the upper and lower eyelids were passively closed for about 1s, and after 30s instillation of the test substance, the test substance was rinsed with a sufficient amount of water flow at a relatively high flow rate but without causing damage to the eyes of the animals for 30s, and the eyes on the right side were not treated as a self-control. The eyes of the animals were examined by instilling for 1h, 24h, 48h, 72h, if necessary, with a slit lamp, sodium fluorescein, and further examined with sodium fluorescein at the time of 24h examination.
(3) Evaluation of results: the degree of irritation of the test object to the eye was evaluated according to the acute eye irritation/corrosiveness test method 5 of the sixth chapter of the safety technical Specification for cosmetics (2015 edition) and the highest integrated mean and recovery time of the irritation response of the cornea, iris or conjunctiva of the animal at 24 hours, 48 hours, 72 hours observation time points, respectively, after administration of the test object, and the results were averaged, as shown in Table 3.
TABLE 3 Table 3
As can be seen from the table data, application example 1 shows acute eye irritation to japanese rabbits: microstimulation under 30s rinse conditions. Application example 1 is explained to be more gentle.
(II) acute skin irritation test
The tested animals are Japanese white rabbits and male animals, 4 animals are adapted to the common environment animal house for 3 days, animal quarantine is completed, and experiments are carried out after animal health is confirmed;
the tested object is amino acid type facial cleanser prepared by application example;
the test method comprises the following steps:
(1) and (3) 24 hours before the test, removing hairs on two sides of the back and the spine of the animal, and not damaging the skin. The dehairing range is about 3cm by 3cm.
(2) The method for contamination comprises the following steps: 0.5mL of the test substance was applied to the left skin in a range of about 2.5 cm. Times.2.5 cm, covered with two layers of gauze (2.5 cm. Times.2.5 cm) and one layer of cellophane, and fixed with a non-irritating adhesive tape. The other side of the skin served as a blank. The test article was applied for 2 hours using a blocking test. After the test, the residual test substance was removed with warm water. The skin reaction at the application site was observed by removing the test substances for 1h, 24h, 48h and 72h, respectively.
(3) Evaluation of results: the skin irritation intensity was evaluated according to the skin irritation/corrosiveness test of the toxicology test method 4 of the sixth chapter of cosmetic safety Specification (2015 edition) and the highest integrated mean value of each observation time point of 24 hours and 48 hours. The results are shown in Table 4.
TABLE 4 Table 4
As can be seen from the table data, the application examples 1 to 3 were free from red spots and red swelling, and the acute skin irritation to Japanese rabbits was: has no irritation. As is clear from application example 1 and comparative application example 1, application example 1 has good mildness.
Test example 4
Human efficacy evaluation test
Selection of the subjects:
1) Inclusion criteria:
(1) Chinese healthy subjects between 18 and 40 years old can be used for men and women;
(2) Positive lactic acid stinging test, total score is more than or equal to 3 score;
(3) Is capable of receiving test area skin inspection and pretreatment;
(4) The course of the test can be understood, voluntarily taking part in the test and signing a written informed consent.
2) Exclusion criteria:
(1) Pregnant or lactating women, or those who have a pregnancy preparation plan recently;
(2) The physique is highly sensitive, allergic diseases and cosmetic allergy history are present;
(3) Cosmetic or other similarly effective products having such an effect have been used within about 2 weeks;
(4) Cosmetic human clinical trials were conducted in approximately 1 month;
(5) Other clinical evaluations were considered unsuitable for participation in the trial.
Subjects 33 persons meeting the inclusion criteria and exclusion criteria described above were selected.
2) The testing process comprises the following steps:
(1) environmental conditions: the test environment is at 21.1-21.6deg.C and humidity of 50.4-55.7% RH;
(2) the using method comprises the following steps: the subjects used the test product in the test area according to the test protocol design.
When a subject cleans the face every day, a proper amount of test product is taken out of the palm, water is added to knead foam, the foam is evenly smeared on the face, the face is gently circled and massaged, and the test product is cleaned by clean water. Long-term sun exposure, outdoor exercises, travel, etc. cannot be performed during the entire test period, and cosmetics or medicines having similar effects to those of the products must not be used, and the subjects must not change the daily care habits during the test period.
1. Subjective evaluations are shown in table 5. The evaluation results are shown in Table 6.
TABLE 5
Lactic acid stinging experimental results and statistical analysis:
TABLE 6-a
| Application example 1 | Mean value of |
| Before use | 4.16 |
| After 2 weeks of use | 1.95 |
Subjective symptom of skin (expert) evaluation results and statistical analysis:
TABLE 6-b
As can be seen from tables 6-a and 6-b, the nasolabial acid stinging score was significantly reduced for 2 weeks using the test product. Application example 1 of the present invention was shown to have a good soothing effect by reducing lactic acid stinging. Compared with the product before application example 1, after the product is used for 2 weeks, the burning, stinging and flushing scores of the whole face skin of the subject are not significantly different, and the itching, reddening and drying scores are significantly improved, so that the application example 1 has excellent mildness and can improve the skin barrier problem.
2. Skin fat content test results and statistical analysis
The results are shown in Table 7, and it is clear from the table that the use of the cleansing product provided in application example 1 can effectively control oil.
TABLE 7
3. Acne count evaluation result and statistical analysis
The results are shown in Table 8, and it is clear from the table that acne can be effectively removed, bacteria can be inhibited and inflammation can be prevented by using the cleansing product provided in application example 1.
TABLE 8
4. Inflammatory papule count evaluation results and statistical analysis
The results are shown in Table 9, and it is found from the table that the use of the cleansing product of application example 1 is effective in suppressing pimples and relieving inflammation. Application example 1 the skin inflammation pimple before use is shown in figure 1 and the skin inflammation pimple after use for 2 weeks is shown in figure 2.
TABLE 9
The applicant states that the process of the invention is illustrated by the above examples, but the invention is not limited to, i.e. does not mean that the invention must be carried out in dependence on the above process steps. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of selected raw materials, addition of auxiliary components, selection of specific modes, etc. fall within the scope of the present invention and the scope of disclosure.
Claims (10)
1. An oil control, soothing and acne-removing composition, characterized in that the oil control, soothing and acne-removing composition comprises: composition I, composition II and composition III;
the composition I comprises gentian extract, cocoa seed extract and madecassoside.
2. The oil control, soothing and acne removing composition of claim 1, wherein said composition II comprises a medicinal layer porus extract and rosewood seed extract.
3. The oil control, soothing and acne removing composition according to claim 1 or 2, wherein the composition III comprises pinus koraiensis leaf extract, lactobacillus fermentation product, mango leaf extract, quaternary ammonium salt-73 and hexamidine bis (hydroxyethylsulfonate).
4. The oil control, relief and acne removal composition according to any one of claims 1 to 3, wherein the mass ratio of composition I, composition II and composition III is (12.7-37): 34-46): 5.6-16.5.
5. The oil control, soothing and acne removing composition according to any one of claims 1 to 4, wherein the composition I comprises 2.5 to 15 parts by weight of gentian extract, 0.2 to 2 parts by weight of cocoa seed extract and 10 to 20 parts by weight of hydroxyasiaticoside.
6. The composition according to any one of claims 1 to 5, wherein the composition II comprises 30 to 40 parts by weight of a medicinal layer porus extract and 4 to 6 parts by weight of a rosewood seed extract.
7. The oil control, relief and acne removal composition according to any one of claims 1-5, wherein composition III comprises, in parts by weight, 1-3 parts of red pine leaf extract, 0.5-3 parts of lactobacillus fermentation product, 2-4.5 parts of mango leaf extract, 0.1-0.5 part of quaternary ammonium salt-73, and 1-5 parts of hexamidine bis (isethionate);
preferably, the oil-control, relieving and acne-removing composition further comprises 0.5-10 parts of butanediol and 0.5-48 parts of water.
8. A method of preparing the oil control, soothing, acne removing composition of any of claims 1-7, comprising: and uniformly mixing the composition I, the composition II and the composition III to obtain the composition.
9. Use of the oil-control, soothing, acne-removing composition according to any one of claims 1 to 7 in a water emulsion, a serum, a cream or a cleansing product.
10. The use according to claim 9, wherein the oil control, soothing and acne removing composition according to any one of claims 1 to 7 in the aqueous emulsion, essence, cream or facial cleansing product is 1 to 2% by mass.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410003167.7A CN117797081A (en) | 2024-01-02 | 2024-01-02 | Oil-control, soothing and acne-removing composition as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410003167.7A CN117797081A (en) | 2024-01-02 | 2024-01-02 | Oil-control, soothing and acne-removing composition as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117797081A true CN117797081A (en) | 2024-04-02 |
Family
ID=90428202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410003167.7A Pending CN117797081A (en) | 2024-01-02 | 2024-01-02 | Oil-control, soothing and acne-removing composition as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117797081A (en) |
-
2024
- 2024-01-02 CN CN202410003167.7A patent/CN117797081A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9381146B2 (en) | Skin conditioner | |
| CN1663559B (en) | Skin normalizing agents | |
| CA2384080C (en) | Skin conditioner | |
| CN109303746B (en) | Prebiotic composition and preparation method and application thereof | |
| CN109431914B (en) | Scalp care composition and application thereof | |
| CN111110577B (en) | Mild mite-removing itching-relieving shower gel and preparation method thereof | |
| EP2883549A1 (en) | Antimicrobial composition comprising filobasidium-suppressing agent derived from natural substance | |
| CN110755331B (en) | Antibacterial infant washing and caring preparation and application thereof | |
| CN111249217A (en) | Cleansing liquid for adjusting skin micro-ecological balance and preparation method thereof | |
| Setiawan et al. | The Effectiveness of Using Aloe Vera Facial Soap and Aloe Gel on the Degree of Acne Vulgaris in Students of SMA Negeri 2 Bayang | |
| CN115569105A (en) | Composition containing rice hull extract for removing dandruff, controlling oil, inhibiting bacteria and removing mites | |
| CN109431913B (en) | Skin microecological balance composition and application thereof | |
| CN116509774B (en) | Anti-dandruff shampoo preparation containing sweet wormwood herb extract and preparation method thereof | |
| CN116850114B (en) | Composition for relieving and repairing and cream for relieving and repairing | |
| CN113749974A (en) | Acne-clearing repairing mask and preparation method thereof | |
| CN116617115B (en) | Mild and tear-free active ingredient composition and application thereof in washing and caring products | |
| CN117797081A (en) | Oil-control, soothing and acne-removing composition as well as preparation method and application thereof | |
| KR20170010499A (en) | Cosmetic Compositions comprising Snail mucus fermentation filtrate for improving skin barrier function and having high skin absorption and Functional Cosmetic using this | |
| CN115919686A (en) | Skin soothing lotion for enhancing skin barrier and preparation method thereof | |
| CN115414308A (en) | Acne removing composition as well as preparation method and application thereof | |
| CN108186440A (en) | Can antibiotic skin-care Chinese medicinal plant shower cream and its preparation method and application | |
| CN110801406A (en) | Multi-effect facial mask repairing liquid and preparation method thereof | |
| KR20110024573A (en) | Cosmetic composition with the effect of atopy skins containing the extract of the rumex cripus l.with high concentrated oxygen water | |
| CN113413331B (en) | Acne-removing composition and preparation and application thereof | |
| CN117224428A (en) | Mild and efficient makeup removing composition, preparation method, makeup removing water, makeup removing foam and makeup removing emulsion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |